Konwerski Michał, Gąsecka Aleksandra, Opolski Grzegorz, Grabowski Marcin, Mazurek Tomasz
1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warszawa, Poland.
Biology (Basel). 2022 Feb 23;11(3):355. doi: 10.3390/biology11030355.
Cardiovascular diseases (CVDs) are the leading causes of death worldwide. Epicardial adipose tissue (EAT) is defined as a fat depot localized between the myocardial surface and the visceral layer of the pericardium and is a type of visceral fat. EAT is one of the most important risk factors for atherosclerosis and cardiovascular events and a promising new therapeutic target in CVDs. In health conditions, EAT has a protective function, including protection against hypothermia or mechanical stress, providing myocardial energy supply from free fatty acid and release of adiponectin. In patients with obesity, metabolic syndrome, or diabetes mellitus, EAT becomes a deleterious tissue promoting the development of CVDs. Previously, we showed an adverse modulation of gene expression in pericoronary adipose tissue in patients with coronary artery disease (CAD). Here, we summarize the currently available evidence regarding the role of EAT in the development of CVDs, including CAD, heart failure, and atrial fibrillation. Due to the rapid development of the COVID-19 pandemic, we also discuss data regarding the association between EAT and the course of COVID-19. Finally, we present the potential therapeutic possibilities aiming at modifying EAT's function. The development of novel therapies specifically targeting EAT could revolutionize the prognosis in CVDs.
心血管疾病(CVDs)是全球主要的死亡原因。心外膜脂肪组织(EAT)被定义为位于心肌表面和心包脏层之间的脂肪库,是一种内脏脂肪。EAT是动脉粥样硬化和心血管事件最重要的危险因素之一,也是心血管疾病中一个有前景的新治疗靶点。在健康状态下,EAT具有保护功能,包括抵御体温过低或机械应力、从游离脂肪酸提供心肌能量供应以及释放脂联素。在肥胖、代谢综合征或糖尿病患者中,EAT成为促进心血管疾病发展的有害组织。此前,我们发现冠心病(CAD)患者冠状动脉周围脂肪组织中基因表达存在不良调节。在此,我们总结了目前关于EAT在心血管疾病(包括CAD、心力衰竭和心房颤动)发展中作用的现有证据。由于COVID-19大流行的迅速发展,我们还讨论了关于EAT与COVID-19病程之间关联的数据。最后,我们介绍了旨在改变EAT功能的潜在治疗可能性。专门针对EAT的新型疗法的开发可能会彻底改变心血管疾病的预后。